Loading today’s stories

Today

AI-assisted reporting, grounded in a per-article claim ledger. Perspective Coverage and Reality Strip separate source viewpoints from evidence, adoption, hype, incentives, and confidence.

Today

Front Page
Today’s Briefing
Newsletters
Trending
For You
Discover
My Stack
Saved
Off Radar
Search

Sections

Security
Build
Invest
Product
Leadership
Science

Company

About
Mission
How this is made
Evidence Index
The desks
The sources we read
Corrections
Press and brand
The daily edition

Trending now

Israeli Tech Ecosystem
Wildfire Smoke
Phishing-as-a-service kits
Teen online safety
AI Copyright Litigation
Agentic AI Risk
H-1B Visa Policy
Local-first AI agents
Venture Funding Rounds
Agentic browsing

How this is made

Today For You My Stack Off Radar Search

Zepbound (KwikPen formulation) — other — Clarity Today

other

Zepbound (KwikPen formulation)

GLP-1 weight-loss drug whose KwikPen formulation is included in Bridge; quoted at a $750 monthly cash price for the patient in this story.

Current clusters

invest1 distinct publisher

Medicare's $50 GLP-1 lane excludes the diagnoses that justify the drug

The Bridge pilot prices by FDA label rather than medical need, routing sicker patients back to Part D copays. KFF's own math assumes three of four eligible people never enroll.

Publishers:fortune.com

Reality

Evidence58
Adoption34
Hype gap+18
Incentives66

Confidence52